Gensight Biologics SA Stock
Price
Target price
€0.19
€0.19
-2.840%
-0.0057
-2.840%
-
05.06.25 / Stuttgart Stock Exchange
WKN: A2ANGZ / Name: Gensight / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Gensight Biologics SA Stock
We can see a decrease in the price for Gensight Biologics SA. Compared to yesterday it has lost -€0.006 (-2.840%).
For the coming years our community has positive and negative things to say abot the Gensight Biologics SA stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Gensight Biologics SA in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gensight Biologics SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | -2.840% | 2.419% | -12.252% | -46.113% | -27.041% | -93.333% | -93.485% |
| Protara Therapeutics Inc. | -4.930% | 0.000% | -6.897% | 13.445% | -47.573% | -15.625% | -94.376% |
| India Globalization Capital | -2.310% | -5.224% | 3.252% | -33.158% | -24.405% | -36.926% | -47.629% |
| Celsion Corp. | 102.780% | -14.620% | 105.634% | 22.689% | 95.973% | -29.808% | -95.944% |
Comments
News
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
Regulatory News:
The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and
GenSight Biologics Annual General Meeting on May 13, 2025
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal